AGP Picks
View all

California Health Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Health Watch.

Press releases published on April 17, 2026

MLR hits LA Sunday: California Legion vs Seattle Seawolves at UCLA Stadium for Community Round presented by Cedars-Sinai
Boston Musician Travels Cross-Country for a Complex Brain Tumor Surgery — And Returns to the Stage Nine Weeks Later
Celebrities Speak Out on Endometriosis, Shining a Spotlight on a Long-Overlooked Women's Health Crisis
Genvor Announces Strategic Memorandum of Understanding with Canlab International(TM) to Advance Peptide Pipeline
Hidden-Incision Breast Augmentation Gains Popularity for Natural Results
Elder Abuse Air Force Surpasses Alzheimer Fundraising Goal. Now launching 'Operation Circle of Protection' for June 15
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Keeps Hair Growth Product Claims Evaluated: Topical & Oral RX Hair Loss Prescription Treatment with Finasteride, Dutasteride & Minoxidil
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
4DMT Announces New Employment Inducement Grants
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Share this page:

Sign up for:

California Health Watch

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.